1126 related articles for article (PubMed ID: 15520202)
1. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.
Tran TT; Uhl M; Ma JY; Janssen L; Sriram V; Aulwurm S; Kerr I; Lam A; Webb HK; Kapoun AM; Kizer DE; McEnroe G; Hart B; Axon J; Murphy A; Chakravarty S; Dugar S; Protter AA; Higgins LS; Wick W; Weller M; Wong DH
Neuro Oncol; 2007 Jul; 9(3):259-70. PubMed ID: 17522330
[TBL] [Abstract][Full Text] [Related]
3. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
4. Glioma gene therapy with soluble transforming growth factor-beta receptors II and III.
Naumann U; Maass P; Gleske AK; Aulwurm S; Weller M; Eisele G
Int J Oncol; 2008 Oct; 33(4):759-65. PubMed ID: 18813789
[TBL] [Abstract][Full Text] [Related]
5. Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line.
Ehata S; Hanyu A; Fujime M; Katsuno Y; Fukunaga E; Goto K; Ishikawa Y; Nomura K; Yokoo H; Shimizu T; Ogata E; Miyazono K; Shimizu K; Imamura T
Cancer Sci; 2007 Jan; 98(1):127-33. PubMed ID: 17129361
[TBL] [Abstract][Full Text] [Related]
6. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.
Friese MA; Wischhusen J; Wick W; Weiler M; Eisele G; Steinle A; Weller M
Cancer Res; 2004 Oct; 64(20):7596-603. PubMed ID: 15492287
[TBL] [Abstract][Full Text] [Related]
7. Microglia-derived TGF-beta as an important regulator of glioblastoma invasion--an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor.
Wesolowska A; Kwiatkowska A; Slomnicki L; Dembinski M; Master A; Sliwa M; Franciszkiewicz K; Chouaib S; Kaminska B
Oncogene; 2008 Feb; 27(7):918-30. PubMed ID: 17684491
[TBL] [Abstract][Full Text] [Related]
8. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.
Suzuki E; Kim S; Cheung HK; Corbley MJ; Zhang X; Sun L; Shan F; Singh J; Lee WC; Albelda SM; Ling LE
Cancer Res; 2007 Mar; 67(5):2351-9. PubMed ID: 17332368
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness.
Gaspar NJ; Li L; Kapoun AM; Medicherla S; Reddy M; Li G; O'Young G; Quon D; Henson M; Damm DL; Muiru GT; Murphy A; Higgins LS; Chakravarty S; Wong DH
Mol Pharmacol; 2007 Jul; 72(1):152-61. PubMed ID: 17400764
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.
Medicherla S; Li L; Ma JY; Kapoun AM; Gaspar NJ; Liu YW; Mangadu R; O'Young G; Protter AA; Schreiner GF; Wong DH; Higgins LS
Anticancer Res; 2007; 27(6B):4149-57. PubMed ID: 18229422
[TBL] [Abstract][Full Text] [Related]
11. Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model.
Ashley DM; Kong FM; Bigner DD; Hale LP
Cancer Res; 1998 Jan; 58(2):302-9. PubMed ID: 9443409
[TBL] [Abstract][Full Text] [Related]
12. EW-7203, a novel small molecule inhibitor of transforming growth factor-β (TGF-β) type I receptor/activin receptor-like kinase-5, blocks TGF-β1-mediated epithelial-to-mesenchymal transition in mammary epithelial cells.
Park CY; Kim DK; Sheen YY
Cancer Sci; 2011 Oct; 102(10):1889-96. PubMed ID: 21707864
[TBL] [Abstract][Full Text] [Related]
13. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
Suzuki E; Kapoor V; Cheung HK; Ling LE; DeLong PA; Kaiser LR; Albelda SM
Clin Cancer Res; 2004 Sep; 10(17):5907-18. PubMed ID: 15355924
[TBL] [Abstract][Full Text] [Related]
14. Combination effect of a TGF-beta receptor kinase inhibitor with 5-FU analog S1 on lymph node metastasis of scirrhous gastric cancer in mice.
Shinto O; Yashiro M; Kawajiri H; Shimizu K; Shimizu T; Miwa A; Hirakawa K
Cancer Sci; 2010 Aug; 101(8):1846-52. PubMed ID: 20518790
[TBL] [Abstract][Full Text] [Related]
15. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta.
Tojo M; Hamashima Y; Hanyu A; Kajimoto T; Saitoh M; Miyazono K; Node M; Imamura T
Cancer Sci; 2005 Nov; 96(11):791-800. PubMed ID: 16271073
[TBL] [Abstract][Full Text] [Related]
16. SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells.
Matsuyama S; Iwadate M; Kondo M; Saitoh M; Hanyu A; Shimizu K; Aburatani H; Mishima HK; Imamura T; Miyazono K; Miyazawa K
Cancer Res; 2003 Nov; 63(22):7791-8. PubMed ID: 14633705
[TBL] [Abstract][Full Text] [Related]
17. Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-beta-mediated activation of the ALK5-Smad 3 pathway.
Yoo YA; Kang MH; Kim JS; Oh SC
Carcinogenesis; 2008 Mar; 29(3):480-90. PubMed ID: 18174246
[TBL] [Abstract][Full Text] [Related]
18. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.
DaCosta Byfield S; Major C; Laping NJ; Roberts AB
Mol Pharmacol; 2004 Mar; 65(3):744-52. PubMed ID: 14978253
[TBL] [Abstract][Full Text] [Related]
19. Pirfenidone inhibits TGF-beta expression in malignant glioma cells.
Burghardt I; Tritschler F; Opitz CA; Frank B; Weller M; Wick W
Biochem Biophys Res Commun; 2007 Mar; 354(2):542-7. PubMed ID: 17234158
[TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
Hayashi T; Hideshima T; Nguyen AN; Munoz O; Podar K; Hamasaki M; Ishitsuka K; Yasui H; Richardson P; Chakravarty S; Murphy A; Chauhan D; Higgins LS; Anderson KC
Clin Cancer Res; 2004 Nov; 10(22):7540-6. PubMed ID: 15569984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
